Navigation Links
MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process

- Validates Position as Leading Innovator in Pharmaceutical Thin Film Technology -

WARREN, N.J., Sept. 11 /PRNewswire/ -- MonoSol Rx, a drug delivery company specializing in quick dissolving thin film pharmaceutical products, today announced that it has been granted U.S. patent No. 7,425,292 from the United States Patent and Trademark Office (USPTO).

The patent, which is expected to issue on September 16, 2008, relates to the Company's proprietary processes for manufacturing a broad range of prescription and over-the-counter products with controlled uniformity of drug content. MonoSol Rx's technology is a major advance for the pharmaceutical industry with its ability to meet the regulatory approval standards for thin film pharmaceutical products. The patent provides broad protection for the Company's drug-containing film manufacturing process and represents the first film patent of its kind to protect the manufacturing process and its ability to insure consistent dosing of medication in each strip. This uniformity is critical to the safety of the patient and is an FDA and global regulatory drug requirement. The patented process also includes steps to preserve the stability of drugs and other active ingredients, by a procedure which permits inclusion of the most sensitive actives in a way which protects them from interacting or losing their potency when the dosage form is manufactured.

"The granting of this patent further validates MonoSol Rx and our PharmFilm(R) technology as leaders and innovators in the field of thin film drug delivery technology. We strive to constantly improve our technology to provide greater benefit to our current and prospective partners and to expand the applicability of thin film to a broader array of drug delivery opportunities and challenges. This patent represents a significant border of protection for MonoSol Rx around the manufacture of its pharmaceutical thin films and will present new challenges for competing companies to achieve uniformity of drug content in a safe, efficient, and cost effective manner," said A. Mark Schobel, President and Chief Executive Officer of MonoSol Rx.

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm(R) technology to deliver drugs in quick dissolving films. PharmFilm(R) is designed to benefit patients by improving the convenience, efficacy, and compliance of currently marketed drugs. The Company is a leader in thin film drug delivery and has a strong intellectual property position, a portfolio of commercialized OTC drug products, and a pipeline of prescription formulations utilizing its PharmFilm(R) technology. With a vertically integrated development and production infrastructure, MonoSol Rx has the capacity to manufacture OTC drug products for near-term revenues that enable the funding of prescription product development programs that will generate long-term value.

The Company's commercialization strategy for all PharmFilm(R) products is to partner with the innovator or other specialty pharma or leading consumer products companies who have the core competency to sell-in and manage the sales and marketing of the products. For the Company's existing and future partners, PharmFilm(R) formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration. PharmFilm(R) is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and ODTs.

About PharmFilm(R)

PharmFilm(R) is a proprietary drug delivery technology that utilizes a novel process and encapsulation compositions to develop easy to use, taste-masked, quick dissolving thin-film drug formulations. PharmFilm(R) delivers a convenient efficacious dose of drug that in some instances can deliver improved therapeutics. PharmFilm's drug delivery advantages significantly benefits patients and their prescribing physicians, and helps improve compliance in pediatric, elderly and other patients who have difficulty swallowing traditional dosage forms.

Media / Investors: Contact:

The Ruth Group MonoSol Rx

Jason Rando / Stephanie Carrington Keith Kendall

(646) 536-7025 / 7017 Chief Financial Officer (732) 564-5000

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Autonomy(TM) Lapro-Angle(TM) Articulating Laparoscopic Instruments Granted CE Mark
2. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
3. Biopure Granted Additional 180 Day Compliance Period by NASDAQ
4. Skinvisible Patent Granted in Australia
5. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
6. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
7. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
8. Kiwa Bio-Tech New Bio-Fertilizer Product Granted Initial Fertilizer Registration Certificate By Ministry of Agriculture of the PRC
9. Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
10. Odyssey Thera Granted U.S. Patent for Animal Imaging
11. ISTO Technologies Granted Key Patent for Cartilage Cell Expansion by the United States Patent Office
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... 2015  Clintrax Global, Inc., a worldwide provider of clinical research ... announced that the company has set a new quarterly earnings record ... quarter growth posted for Q3 of 2014 to Q3 of 2015. ... Mexico , with the establishment of an Asia-Pacific ... United Kingdom and Mexico ...
(Date:11/24/2015)... 24, 2015 --> ... report released by Transparency Market Research, the global non-invasive ... CAGR of 17.5% during the period between 2014 and ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ... testing market to reach a valuation of US$2.38 bn ...
Breaking Biology Technology:
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
(Date:10/23/2015)... Oct. 23, 2015 Research and Markets ( ... "Global Voice Recognition Biometrics Market 2015-2019" report to ... --> The global voice recognition biometrics market to ... --> --> The ... prepared based on an in-depth market analysis with inputs ...
(Date:10/22/2015)... 2015  Synaptics (NASDAQ: SYNA ), a leading developer of ... ended September 30, 2015. --> ... grew 66 percent over the comparable quarter last year to $470.0 ... $23.8 million, or $0.62 per diluted share. ... quarter of fiscal 2016 grew 39 percent over the prior year ...
Breaking Biology News(10 mins):